Teva, Sanofi announce results from Phase 2b RELIEVE UCCD study

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), and Sanofi (SNY) announce that the Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis and Crohn’s disease. RELIEVE UCCD investigated duvakitug, a human IgG1-2 monoclonal antibody targeting TL1A, for the treatment of moderate-to-severe inflammatory bowel disease. In the RELIEVE UCCD study, 36.2% and 47.8% of patients with UC treated with duvakitug achieved clinical remission compared to 20.45% on placebo, placebo-adjusted rates were 15.7% and 27.4%, at week 14. In patients with CD, 26.1% and 47.8% treated with duvakitug achieved endoscopic response compared to 13.0% on placebo, placebo-adjusted rates were 13.0% and 34.8%, at week 14. Overall, the treatment effect was consistent across subgroups. This is the first and only randomized, placebo-controlled study to evaluate the impact of an anti-TL1A monoclonal antibody in CD. Detailed results are expected to be presented at a scientific forum in 2025. Duvakitug was generally well tolerated in both UC and CD with no safety signal identified